The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.
Researchers evaluated the safety and efficacy of tofacitinib for the treatment of patients with ankylosing spondylitis.
Study authors reported on the 1-year safety and efficacy of guselkumab treatment in patients with active psoriatic arthritis.
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.
Researchers assessed whether the gut microbiome in ankylosing spondylitis and inflammatory bowel disease was different, and whether it correlated with disease activity.
Researchers evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis.
Researchers explored the determinants of impaired spinal and hip mobility in patients with early axial spondyloarthritis.
Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.
Survival and discontinuation rates of infliximab when treating psoriasis in real world conditions were analyzed.